-
公开(公告)号：US20240391931A1
公开(公告)日：2024-11-28
申请号：US18294280
申请日：2022-08-04
Applicant: Bristol-Myers Squibb Company
Inventor： Laura Akullian D'Agostino , Xinchao Chen , Claudio Emundo Chuaqui , Hormoz Mazdiyasni , Guobin Miao , Deqiang Niu
IPC: C07D495/14 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/69 , A61P35/00 , C07D471/14 , C07D519/00 , C07F5/02
Abstract: Provided herein are tricyclic fused pyrimidine compounds, and pharmaceutically acceptable salts thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
-
公开(公告)号：US20240327381A1
公开(公告)日：2024-10-03
申请号：US18435117
申请日：2024-02-07
Applicant: Celgene Corporation , Bristol-Myers Squibb Company
Inventor： Laura Akullian D'Agostino , Godwin Kumi , Haibo Liu
IPC: C07D401/14 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , C07D401/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D451/00 , C07D471/04
CPC classification number: C07D401/14 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , C07D401/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D451/00 , C07D471/04
Abstract: Provided herein are compounds and compositions thereof for degrading an engineered polypeptide in a cell. In some embodiments, the compounds and compositions are provided for treatment of cancer.
-
公开(公告)号：US12162848B2
公开(公告)日：2024-12-10
申请号：US18161184
申请日：2023-01-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Haibo Liu , Laura Akullian D'Agostino , Shoshana L. Posy , Annapurna Pendri , Swanee E. Jacutin-Porte
IPC: C07D285/06 , A61K45/06 , A61P35/00 , C07D417/10 , C07D417/12
Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.
-
-
Search Results
3
records
(took 0.01 seconds)
